Hypertension frequently resists control with monotherapy, requiring two or more antihypertensive agents in combination. Many antihypertensive fixed-dose combinations (FDCs) combine drugs with different, but complementary, mechanisms of action to improve overall efficacy and tolerability. Antihypertensive FDCs may provide significant advantages over high-dose monotherapy, such as improved efficacy in blood pressure control, reduced adverse events, improved patient compliance and lower treatment costs. Optimal blockade of the reninangiotensin-aldosterone system is a key goal of pharmacotherapy in cardiovascular as well as in renal disease. As the conversion of angiotensinogen into angiotensin I is the rate-limiting step in the synthesis of angiotensin II, it has been suggested that renin inhibitors like aliskiren may have comparable or superior clinical efficacy to angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). Evidences supports that amlodipine, a calcium channel blocker is safe and effective antihypertensive agent. Various clinical trials have demonstrated the efficacy and tolerability of amlodipine in combination with ACE inhibitors and ARBs. By reviewing the clinical trials of combination of aliskiren and amlodipine in hypertensive patients, it has been found that this US FDA approved combination is effective in reducing blood pressure and having better safety profile.
INTRODUCTION
Various extensive studies have demonstrated that the achievement of blood pressure goals in hypertensive patients is certainly possible; albeit, the great majority will eventually require two or more antihypertensive agents. [1] There are many fixeddose combinations (FDCs) that can be used for the treatment of hypertension, including angiotensin converting enzyme (ACE) inhibitor/diuretic, angiotensin receptor blocker (ARB)/diuretic, β-blocker/diuretic, ACE inhibitor/calcium channel blocker (CCB) and ARB/CCB regimens. Potential advantages of FDCs for the treatment of hypertension includes, i) increased medication adherence and convenience of use; ii) potentiation of antihypertensive effects of single compounds; iii) additive or synergistic effects; iv) enhancing effect in specific populations; v) attenuation of adverse events; vi) improved overall results, greater blood pressure control, and lower cost. [2] Recently, combination of aliskiren (renin inhibitor)/amlodipine (CCB) has been approved by the United States Food and Drug Administration (US FDA) on August 2010 for treatment of hypertension.
Optimal blockade of the renin-angiotensinaldosterone system is a key goal of pharmacotherapy in cardiovascular and renal disease. Since renincatalyzed conversion of angiotensinogen into angiotensin I is the rate-limiting step in the synthesis of angiotensin II, it has been suggested that renin inhibition may have comparable or superior clinical efficacy to ACE inhibitors and ARBs. [3] The therapeutic effect of renin inhibitors is distinct from that of ACE inhibitor or ARB therapy in that the resultant decrease in angiotensin II production eliminates concern for both ACE-independent angiotensin II generation (which occurs with chronic ACE inhibitor therapy) and compensatory angiotensin II production (which occurs with chronic ARB therapy). Aliskiren, one of the most potent inhibitors of human renin, is the first agent in this class of drugs that have been evaluated systematically for its effectiveness and safety in the treatment of animal and human hypertension. [4] Dahlof et al, reported a pooled analysis of 8481 patients who participated in double-blind, placebocontrolled clinical trials comparing the effects of 150 mg and 300 mg dosages of aliskiren monotherapy with placebo for 8 to 12 weeks. Statistically significant reductions in systolic blood pressure (SBP) and diastolic blood pressure (DBP) were achieved compared with placebo. The aliskiren treatment arms were well tolerated and had side effects comparable to placebo.
[5]
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Amlodipine with ACE inhibitors or ARBs
Efficacy and tolerability of amlodipine in combination with ACE inhibitors and ARBs have been studied in various clinical trials. A total of 17 randomized controlled trials involving 3291 patients showed that the combination treatment of amlodipine and ACE inhibitors resulted in a greater reduction of both SBP and DBP than monotherapy. The combination treatment also caused significantly greater reductions for the mean ambulatory SBP and DBP during the full 24 hours, but not for the trough. The hypertension therapeutic control (SPB <140, DBP <90 mmHg) rate for the combination treatment was higher than that for monotherapy. Further, the combination treatment also resulted in a lower overall rate of adverse events and edema, but a higher rate of cough as compared with monotherapy. [6] The American COACH (Combination of Olmesartan Medoxomil and Amlopdine Besylate in Controlling High Blood Pressure) study was a multicentre, randomized, double-blind, placebo controlled, factorial design enrolling 1,940 patients showed that after 8 weeks of treatment the blood pressure goals were most frequently achieved in the combination therapy group with 56.3% and 54.0% of patients reaching adequate blood pressure of <140/90 mmHg with olmesartan/amlodipine 20/10 and 40/10 respectively. Also, the combination therapy was well tolerated and was associated with a lower incidence of side effects, such as edema, compared to monotherapy with amlodipine 10 mg. [7] The ADHT (Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial), a double-blind, double-dummy, 22 week trial evaluated the efficacy and safety of adding amlodipine to the treatment regimen of patients with hypertension and diabetes who were already receiving either quinapril or losartan as monotherapy. Blood pressure goal was reached by 27.5% of patients when amlodipine was added to quinapril or losartan monotherapy, compared with 12.5% when placebo was added. When added to quinapril or losartan monotherapy, amlodipine reduced blood pressure by 8.1/5.4 mm Hg, compared with a 1.6/0.7 mm Hg decrease with add-on placebo (P < 0.001). Also, amlodipine, quinapril, and losartan were well tolerated. [8] Aliskiren/amlodipine combination Various clinical studies have investigated the safety and efficacy of aliskiren/amlodipine combination. In a randomized, double-blind, active-controlled, parallel-group multicenter study, 545 patients with mild-moderate hypertension who did not respond to amlodipine 5 mg daily received aliskiren 150 mg/amlodipine 5 mg daily, amlodipine 10 mg daily, or continued amlodipine 5 mg daily for 6 weeks. Aliskiren/amlodipine combination therapy led to significant SBP and DBP reductions when compared with amlodipine 5 mg monotherapy, but the effect did not surpass amlodipine 10 mg daily. However, amlodipine 10 mg daily was associated with significant peripheral edema compared with dual aliskiren/amlodipine therapy. [9] In an open-label study, aliskiren/amlodipine combination therapy provided a mean blood pressure reduction from baseline to week 54 of 24.2/15.5 mmHg; 74.3% of patients achieved blood pressure control. In the subgroup of patients with stage 2 hypertension (baseline mean sitting SBP > or =160 mmHg and/or mean sitting DBP > or =100 mmHg), the mean blood pressure reduction at week 54 was 29.1/17.1 mmHg, and 67.0% of patients achieved blood pressure control. The most frequently reported adverse events were peripheral edema, upper respiratory tract infection, headache and bronchitis. [10] Recently, a double-blind, randomised, parallelgroup, superiority trial (ACCELERAE) showed that the patients given initial combination therapy of aliskiren/amlodipine had a 6.5 mm Hg greater reduction in mean systolic blood pressure than the monotherapy groups of aliskiren and amlodipine (P < 0.0001) while at 24 weeks, when all patients were on combination treatment, the difference was 1.4 mm Hg (P = 0.059). Adverse events like peripheral oedema, hypotension, or orthostatic hypotension caused withdrawal of 14% patients from the initial aliskiren/amlodipine group compared to 14% from the aliskiren group and 18% from the amlodipine group. [11] The US FDA approval of combination of aliskiren/amlodipine was based on clinical trial data involving more than 5,000 patients with mild-tomoderate high blood pressure. A 8 week, randomized, double-blind, placebo-controlled, multifactorial study (Study One) showed that the combination of aliskiren/amlodipine resulted in decreases in systolic/diastolic blood pressure at trough of 14-17/9-11 mmHg, compared to 4-9/3-4 mmHg for aliskiren alone, and 9-14/6-8 mmHg for amlodipine alone. Another double-blind, activecontrolled study (Study Two) enrolled 443 AfricanAmericans with moderate-to-severe high blood pressure (SBP 160 -200 mmHg). The systolic/diastolic treatment difference between aliskiren/amlodipine combination and amlodipine was 5.2/3.8 mmHg at 8 weeks. Another doubleblind, active-controlled (Study Three) enrolled 484 subjects with moderate-to-severe high blood pressure (SBP 160 -200 mmHg). The treatment difference between aliskiren/amlodipine combination and amlodipine was 7.1/3.8 mmHg at endpoint. [12] A large number of evidence supports the notion that amlodipine (the prototypical long-acting secondgeneration dihydropyridine CCB) is safe and effective agent for the treatment of hypertension, which has been shown to lower blood pressure both as a monotherapy and in combination with other antihypertensive agents. [13] On the other side, although the antihypertensive potency of aliskiren is equivalent to those of ARBs, ACE inhibitors, and diuretics, critical questions regarding the effectiveness of aliskiren in blocking the effects of renin/pro-renin at the site of the (pro)renin receptor remain to be answered. [14] To sum up, currently available information from clinical trials involving use of aliskiren/amlodipine combination suggest that this combination is effective in reducing blood pressure and having better safety profile.
